CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Aspirin +1 moredrug
Likely dose
Aspirin 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00861341
NCT00861341Phase 2Completed
CompareCT.gov

Effects of Pioglitazone on Platelet Function

University of Rochester·interventional·Posted Mar 13, 2009·Updated Feb 3, 2016

In Brief

A Phase 2 clinical trial evaluating Aspirin and Pioglitazone for Diabetes and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine how pioglitazone and aspirin affect platelets in the blood of diabetic and non-diabetic subjects. Platelets are small cells in the blood that help with blood clotting. Pioglitazone is a drug that is used to lower blood sugar and fats by helping the body to use insulin correctly. Pioglitazone is presently used to treat diabetes but has not been approved for non-diabetics. This study will determine whether pioglitazone reduces the activity of platelets in people who are or are not also taking aspirin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Platelet Function, Healthy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 13, 2009
Enrollment StartDec 1, 2008
Primary CompletionJun 1, 2010
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.3 years ago

Interventions

Aspirindrug

81 mg

Pioglitazonedrug

30mg Pioglitazone x1